Expanding on our prior observations in neuroblastoma (Wei et al., 2018), we noted appreciable differences in TIL enrichment pattern (Figure 1A) and expressional levels of immune checkpoints between MYCN-not amplified (MYCN.NA) and MYCN-amplified (MYCN.A) tumors (Figure 2A). The gene discussed is MYCN; the disease is neuroblastoma.